Effectiveness of KOS-862 in the Treatment of Lung Cancer

Bristol-Myers Squibb (BMS)

Status and phase: Terminated; Phase 2

Conditions: Lung Cancer

Treatments: Drug: KOS-862

Study type: Interventional

Funder types: Industry

Identifiers

NCT00080509

KOS-201/NO17352

Details and patient eligibility

About

The purpose of this study is to determine whether a potential drug known as KOS-862 or "Epothilone D" has an effect as a 2nd line treatment in non-small cell lung cancer (NSCLC) for patients having failed one prior platinum-containing chemotherapy regimen.

Full description

To determine the antitumor activity, based on the confirmed objective response rate, of KOS-862, administered intravenously weekly for 3 weeks every 4 weeks, in patients with non-small cell lung cancer (NSCLC) whose disease has progressed following initial chemotherapy for advanced or metastatic disease.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• At least 18 years of age
• Measurable disease
• One previous treatment of a platinum based drug such as cisplatin or carboplatin
• At least 3 weeks since last surgery/radiation/chemotherapy

Exclusion criteria

• Brain metastases
• Changes in the rhythm of your heart that are considered significant as determined by an ECG tracing

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)